Compare EOI & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Eaton Vance Enhance Equity Income Fund Eaton Vance Enhanced Equity Income Fund Shares of Beneficial Interest
Current Price
| Metric | EOI | NUVB |
|---|---|---|
| Founded | N/A | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 817.2M | 2.0B |
| IPO Year | 2004 | 2020 |
| Metric | EOI | NUVB |
|---|---|---|
| Price | $20.02 | $6.81 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $11.38 |
| AVG Volume (30 Days) | 65.1K | ★ 5.2M |
| Earning Date | 01-01-0001 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 71.56 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $62,902,000.00 |
| Revenue This Year | N/A | $203.82 |
| Revenue Next Year | N/A | $58.18 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 698.96 |
| 52 Week Low | $18.04 | $3.00 |
| 52 Week High | $21.44 | $9.75 |
| Indicator | EOI | NUVB |
|---|---|---|
| Relative Strength Index (RSI) | 52.54 | 52.31 |
| Support Level | $19.43 | $5.28 |
| Resistance Level | $20.16 | $6.80 |
| Average True Range (ATR) | 0.18 | 0.37 |
| MACD | -0.02 | -0.04 |
| Stochastic Oscillator | 60.84 | 41.38 |
Eaton Vance Enhanced Equity Income Fund offers mutual funds that invest across a wide array of equity, income, and alternative strategies. The primary investment objective of the fund is to provide current income, with a secondary objective of capital appreciation. The company's sector allocation includes: Information Technology, Communication Services, Financials, Consumer Discretionary, Healthcare, Industries, Consumer Staples, Energy, Real Estate, and Materials.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.